Comparative Efficacy and Safety of Osimertinib Versus First-Generation EGFR-TKIS as First-Line Treatment in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Objective of this study was to compare the efficacy and safety of Osimertinib versus first-generation EGFR-TKIs (gefitinib, erlotinib) as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) through a systematic review and meta-analysis. A systematic review was conducted follow...